Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies
| Autor: | Neelakshi Mungra, Guillaume Vignaux, Jean Engohang-Ndong, Eden Padayachee, Jean De La Croix Ndong, Fleury Augustin Nsole Biteghe, Stefan Barth, Nyangone Ekome Toung Chalomie, Krupa Naran |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.drug_class medicine.medical_treatment Review Biology Monoclonal antibody Epitope 03 medical and health sciences 0302 clinical medicine Cancer immunotherapy medicine Panitumumab targeted human cytolytic fusion proteins (hCFPs) Epidermal growth factor receptor Deimmunization Cetuximab epidermal growth factor receptor (EGFR) recombinant antibody-drug conjugates (rADCs) recombinant antibody photoimmunoconjugates (rAPCs) 030104 developmental biology Oncology recombinant immunotoxins (ITs) 030220 oncology & carcinogenesis Cancer research biology.protein Hybridoma technology medicine.drug |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.27730 |
| Popis: | The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angiogenesis. This multi-dimensional role of EGFR in the progression and aggressiveness of cancer, has evolved from conventional to more targeted therapeutic approaches. With the advent of hybridoma technology and phage display techniques, the first anti-EGFR monoclonal antibodies (mAbs) (Cetuximab and Panitumumab) were developed. Due to major limitations including host immune reactions and poor tumor penetration, these antibodies were modified and used as guiding mechanisms for the specific delivery of readily available chemotherapeutic agents or plants/bacterial toxins, giving rise to antibody-drug conjugates (ADCs) and immunotoxins (ITs), respectively. Continued refinement of ITs led to deimmunization strategies based on depletion of B and T-cell epitopes or substitution of non-human toxins leading to a growing repertoire of human enzymes capable of inducing cell death. Similarly, the modification of classical ADCs has resulted in the first, fully recombinant versions. In this review, we discuss significant advancements in EGFR-targeting immunoconjugates, including ITs and recombinant photoactivable ADCs, which serve as a blueprint for further developments in the evolving domain of cancer immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|